Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amgen ( (AMGN) ) has provided an announcement.
Amgen announced on May 19, 2026 that Executive Vice President and Chief Financial Officer Peter Griffith, who has held the CFO role since 2020, will retire effective Aug. 31, 2026 and remain as an executive vice president in a non-officer capacity through January 2027 to ensure a smooth handover. The move caps a tenure in which Griffith strengthened Amgen’s financial foundation, supported disciplined capital allocation and helped advance the company’s long-term growth strategy, underscoring continuity for investors during the transition.
In conjunction with Griffith’s retirement, the board approved the appointment of veteran finance executive Thomas Dittrich, 62, as executive vice president effective July 1, 2026 and as CFO from Sept. 1, 2026, with Dittrich initially based in Rotkreuz, Switzerland before relocating to Thousand Oaks. Dittrich, who previously held senior finance roles at Amgen and has served as CFO at Galderma, Shire and Sulzer, will oversee all financial operations under a rich compensation and retention package designed to offset forgone pay and secure his services, signaling Amgen’s commitment to experienced financial leadership as it pursues long-term growth.
The most recent analyst rating on (AMGN) stock is a Buy with a $427.00 price target. To see the full list of analyst forecasts on Amgen stock, see the AMGN Stock Forecast page.
Spark’s Take on AMGN Stock
According to Spark, TipRanks’ AI Analyst, AMGN is a Neutral.
The score is primarily supported by strong operating profitability and cash generation and a constructive earnings update (raised guidance and continued growth-driver momentum). It is held back by elevated leverage and only middling technical momentum, with valuation appearing fair rather than clearly compelling.
To see Spark’s full report on AMGN stock, click here.
More about Amgen
Amgen is a U.S.-based biotechnology company that discovers, develops, manufactures and delivers innovative medicines targeting some of the world’s toughest diseases, including cancer, inflammatory conditions, rare diseases, heart disease and obesity-related conditions. Founded more than 45 years ago in Thousand Oaks, Calif., it helped establish the biotechnology industry and now reaches millions of patients worldwide with a broad pipeline and portfolio, and is a constituent of both the Dow Jones Industrial Average and the Nasdaq-100 Index.
Average Trading Volume: 2,655,526
Technical Sentiment Signal: Buy
Current Market Cap: $176.1B
For detailed information about AMGN stock, go to TipRanks’ Stock Analysis page.